Shopping Cart

Your shopping cart is currently empty

Semaglutide

Name: Semaglutide
Brand: TargetMol
SKU: T19850
Price: 77 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Hot

Synonyms:

Catalog No. T19850 Copy Product Info

Purity: 99.78%

😃Good

Hot

Semaglutide is a long-acting, selective, competitive GLP-1R agonist and a long-acting analog of human glucagon-like peptide-1, exhibiting potent hypoglycemic, weight-loss, cardioprotective, and neuroprotective effects. Upon activation of the GLP-1R, semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, while also enhancing autophagy and suppressing oxidative stress and apoptosis. Semaglutide also plays a role in regulating mitochondrial function and lipid metabolism. Semaglutide is being investigated for use in type 2 diabetes, obesity, Parkinson’s disease, metabolic and fatty liver diseases (MASLD), and other neurodegenerative and liver diseases, as well as in cancer research.

Cas No. 910463-68-2

Pack Size	Price	USA Stock	Global Stock
500 μg	$77	In Stock	In Stock
1 mg	$128	In Stock	In Stock
5 mg	$278	In Stock	In Stock
10 mg	$397	In Stock	In Stock
25 mg	$592	In Stock	In Stock
50 mg	$822	In Stock	In Stock
100 mg	$1,110	In Stock	In Stock
200 mg	$1,494	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.78%

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	Semaglutide is a long-acting, selective, competitive GLP-1R agonist and a long-acting analog of human glucagon-like peptide-1, exhibiting potent hypoglycemic, weight-loss, cardioprotective, and neuroprotective effects. Upon activation of the GLP-1R, semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, while also enhancing autophagy and suppressing oxidative stress and apoptosis. Semaglutide also plays a role in regulating mitochondrial function and lipid metabolism. Semaglutide is being investigated for use in type 2 diabetes, obesity, Parkinson’s disease, metabolic and fatty liver diseases (MASLD), and other neurodegenerative and liver diseases, as well as in cancer research.
Targets & IC50	albumin:27 µM, GLP1 receptor:6.2 pM (EC50)
In vitro	Methods: Cell viability was assessed using the MTT assay 24 hours after treating SH-SY5Y cells with 75 μM 6-OHDA and 1–100 nM Semaglutide. Results: 6-OHDA significantly reduced cell viability, while Semaglutide significantly reversed the damage. [2]
In vivo	Methods: Mice made obese by a high-fat diet (DIO mice) were administered subcutaneous injections of Semaglutide (1, 3, 10, 30, 100 nmol/kg). Body weight, food intake, and body composition were measured 21 days later. Results: Semaglutide reduced body weight and food intake in a dose-dependent manner; the highest dose (100 nmol/kg) resulted in a 22% decrease in body weight (from 43.6 g to 34.8 g). [1] Methods: A doxorubicin-induced (5 mg/kg/week, intraperitoneal injection for 4 weeks) cardiac toxicity model was established in C57/BL6J mice. Semaglutide (12 μg/kg/day, subcutaneous injection for 6 weeks) was administered as an intervention, and cardiac function was assessed via echocardiography and invasive hemodynamic monitoring. Results: Doxorubicin caused impaired cardiac function and elevated myocardial injury markers in mice. Semaglutide significantly improved cardiac function, reduced injury markers, and increased mouse survival rates. Furthermore, Semaglutide inhibited oxidative stress and repaired mitochondrial dysfunction. [3] Methods: A Parkinson’s disease model was established in SD rats via 6-OHDA-induced unilateral medial forebrain bundle injury, followed by intraperitoneal administration of 25 nmol/kg Semaglutide (once every 2 days for a total of 31 days). Results: Semaglutide significantly improved neurological damage in the model rats. [4]

Chemical Properties

Molecular Weight	4114
Formula	C₁₈₇H₂₉₁N₄₅O₅₉
Cas No.	910463-68-2
Smiles	CC[C@@H]([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC(C(C)(NC([C@@H](N)CC1=CN=CN1)=O)C)=O)CCC(O)=O)=O)=O)[C@H](O)C)=O)CC2=CC=CC=C2)=O)[C@H](O)C)=O)CO)=O)CC(O)=O)=O)C(C)C)=O)CO)=O)CO)=O)CC3=CC=C(O)C=C3)=O)CC(C)C)=O)CCC(O)=O)=O)=O)CCC(N)=O)=O)C)=O)C)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](NC(CCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)=O)CCC(O)=O)=O)CC4=CC=CC=C4)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(O)=O)=O)CCCNC(N)=N)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CC(C)C)=O)CC5=CNC6=CC=CC=C65)=O)C)=O)C
Relative Density.	no data available
Sequence	His-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-{Lys(AEEA-AEEA-γGlu-C18 diacid)}-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Sequence Short	HXEGTFTSDVSSYLEGQAAEEFIAWLVRGRG

Storage & Solubility Information

Storage

Keep away from moisture,Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: 10 mg/mL (2.43 mM), when pH is adjusted to 14 with NaOH. Sonication and heating are recommended.

H2O: insoluble

DMSO: 50 mg/mL (12.15 mM), Sonication is recommended.

H2O: 5 mg/mL (1.22 mM), when pH is adjusted to 1 with HCl. Sonication and heating are recommended.

Solution Preparation Table

H2O/H2O/DMSO

	1mg	5mg	10mg	50mg
1 mM	0.2431 mL	1.2154 mL	2.4307 mL	12.1536 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.